Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein.

Nguyen HT, Madani N, Ding H, Elder E, Princiotto A, Gu C, Darby P, Alin J, Herschhorn A, Kappes JC, Mao Y, Sodroski JG.

Virol J. 2017 Feb 16;14(1):33. doi: 10.1186/s12985-017-0704-x.

2.

Evolution of B cell analysis and Env trimer redesign.

Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT.

Immunol Rev. 2017 Jan;275(1):183-202. doi: 10.1111/imr.12515. Review.

PMID:
28133805
3.

Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV.

Rodriguez-Garcia M, Shen Z, Barr FD, Boesch AW, Ackerman ME, Kappes JC, Ochsenbauer C, Wira CR.

Mucosal Immunol. 2017 Mar;10(2):531-544. doi: 10.1038/mi.2016.72. Epub 2016 Aug 31.

4.

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies.

Feng Y, Tran K, Bale S, Kumar S, Guenaga J, Wilson R, de Val N, Arendt H, DeStefano J, Ward AB, Wyatt RT.

PLoS Pathog. 2016 Aug 3;12(8):e1005767. doi: 10.1371/journal.ppat.1005767. eCollection 2016 Aug.

5.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

6.

Maturational characteristics of HIV-specific antibodies in viremic individuals.

Meffre E, Louie A, Bannock J, Kim LJ, Ho J, Frear CC, Kardava L, Wang W, Buckner CM, Wang Y, Fankuchen OR, Gittens KR, Chun TW, Li Y, Fauci AS, Moir S.

JCI Insight. 2016;1(3). pii: e84610. Epub 2016 Mar 17.

7.

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.

Apostólico Jde S, Boscardin SB, Yamamoto MM, de Oliveira-Filho JN, Kalil J, Cunha-Neto E, Rosa DS.

PLoS One. 2016 Jan 4;11(1):e0145637. doi: 10.1371/journal.pone.0145637. eCollection 2016.

8.
9.

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.

Sattentau QJ.

Vaccines (Basel). 2013 Oct 28;1(4):497-512. doi: 10.3390/vaccines1040497. Review.

10.

Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Zhang H, Fu H, Luallen RJ, Liu B, Lee FH, Doms RW, Geng Y.

Vaccine. 2015 Sep 22;33(39):5140-7. doi: 10.1016/j.vaccine.2015.08.012. Epub 2015 Aug 13.

11.

Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes.

Peters PJ, Gonzalez-Perez MP, Musich T, Moore Simas TA, Lin R, Morse AN, Shattock RJ, Derdeyn CA, Clapham PR.

Retrovirology. 2015 Jun 9;12:48. doi: 10.1186/s12977-015-0176-2.

12.

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.

Bowles EJ, Schiffner T, Rosario M, Needham GA, Ramaswamy M, McGouran J, Kessler B, LaBranche C, McMichael AJ, Montefiori D, Sattentau QJ, Hanke T, Stewart-Jones GB.

PLoS One. 2014 Dec 9;9(12):e114709. doi: 10.1371/journal.pone.0114709. eCollection 2014.

13.
14.

Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69.

15.

Modulation of HIV-1 immunity by adjuvants.

Moody MA.

Curr Opin HIV AIDS. 2014 May;9(3):242-9. doi: 10.1097/COH.0000000000000052. Review.

16.

HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P.

Tuluc F, Meshki J, Spitsin S, Douglas SD.

J Leukoc Biol. 2014 Jul;96(1):143-50. doi: 10.1189/jlb.4AB0813-434RR. Epub 2014 Feb 27.

17.

Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Nkolola JP, Cheung A, Perry JR, Carter D, Reed S, Schuitemaker H, Pau MG, Seaman MS, Chen B, Barouch DH.

Vaccine. 2014 Apr 11;32(18):2109-16. doi: 10.1016/j.vaccine.2014.02.001. Epub 2014 Feb 18.

18.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A.

Virology. 2014 Jan 5;448:363-74. doi: 10.1016/j.virol.2013.10.007. Epub 2013 Nov 12.

19.

Antigenic properties of the HIV envelope on virions in solution.

Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL.

J Virol. 2014 Feb;88(3):1795-808. doi: 10.1128/JVI.03048-13. Epub 2013 Nov 27. Erratum in: J Virol. 2014 May;88(10):5901. Yu, Lei [added].

20.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium..

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

Supplemental Content

Support Center